Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENAPAX vs COARTEM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gepirone is a 5-HT1A receptor partial agonist, enhancing serotonergic neurotransmission in brain regions implicated in mood regulation.
Artemether and lumefantrine are antimalarial agents that act as blood schizonticides. Artemether is rapidly metabolized to dihydroartemisinin, which generates free radicals that damage parasite proteins and membranes. Lumefantrine inhibits the formation of beta-hematin (hemozoin) by forming a complex with hemin, thereby preventing parasite detoxification of heme.
Treatment of major depressive disorder (MDD)
Treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum,Treatment of uncomplicated malaria due to Plasmodium vivax (in combination with primaquine for radical cure)
Oral: 500 mg twice daily. Intravenous: 500 mg over 1 hour every 6 hours.
4 tablets (each containing artemether 20 mg and lumefantrine 120 mg) orally twice daily for 3 days (total of 6 doses). Doses should be taken with fatty food to enhance absorption. Repeat dosing if vomiting occurs within 1 hour after administration.
Terminal elimination half-life: 18-24 hours in adults with normal renal function, prolonged to >40 hours in severe renal impairment (Cr Cl <30 m L/min).
Artemether: terminal elimination half-life ~1–3 hours (rapid, consistent with its role in rapid parasite clearance). Lumefantrine: terminal elimination half-life ~4–6 days (mean 4.5 days in healthy volunteers; longer in malaria patients due to increased Vd and protein binding). The prolonged half-life of lumefantrine ensures effective post-treatment prophylaxis.
Primarily via CYP3A4; also minor routes via CYP2D6 and aldehyde oxidase.
Artemether is metabolized primarily by CYP3A4 and CYP3A5 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Primarily renal excretion of unchanged drug (approximately 80%); biliary/fecal elimination accounts for 15%; the remainder is metabolized.
Artemether is primarily metabolized in the liver via CYP3A4; its metabolites are excreted in feces (approximately 80%) and urine (minor). Lumefantrine is also hepatically metabolized (CYP3A4) and excreted predominantly in feces (90%) with minimal renal excretion (<1%). Overall, both drugs are eliminated mainly via biliary/fecal routes. Renal excretion is negligible.
95% bound to serum albumin and alpha-1-acid glycoprotein (AAG).
Artemether: >95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Lumefantrine: >99% bound to plasma proteins (mainly albumin and α1-acid glycoprotein).
2–4 L/kg, indicating extensive tissue distribution (e.g., liver, kidney, lung) with potential for accumulation in erythrocytes.
Artemether: Vd ~2–4 L/kg (large, indicating extensive tissue distribution). Lumefantrine: Vd ~10–20 L/kg (very large, suggesting deep tissue compartment, likely due to high lipophilicity and protein binding).
Oral: 60–75% (first-pass metabolism); Intravenous: 100%.
Oral bioavailability of Coartem fixed-dose combination: artemether ~40% (with food) but highly variable; absorption is enhanced by fat. Lumefantrine oral bioavailability is highly variable (approximately 20–50%) and significantly increased when taken with food (especially fatty meals). Coartem should be taken with food to maximize absorption.
GFR 30-59 m L/min: 250 mg twice daily. GFR 15-29 m L/min: 250 mg once daily. GFR <15 m L/min: 250 mg every 48 hours.
No dose adjustment required for mild to moderate renal impairment. Safety and efficacy not established in severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Contraindicated in severe hepatic impairment (Child-Pugh class C).
10-15 mg/kg/dose every 12 hours orally or intravenously, max 500 mg/dose.
Weight-based dosing: 5-15 kg: 1 tablet per dose; 15-25 kg: 2 tablets per dose; 25-35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer orally twice daily for 3 days (total of 6 doses) with fatty food.
Start at 250 mg twice daily; adjust based on renal function.
No specific dose adjustment required; follow adult dosing. Caution in elderly due to potential for QT prolongation and concurrent medications. Monitor for cardiac effects.
None.
None.
QTc prolongation risk, particularly in patients with hypokalemia, hypomagnesemia, or concurrent use of QTc-prolonging drugs.,Serotonin syndrome risk with coadministration of other serotonergic drugs.,Avoid use with MAOIs or within 14 days of MAOI discontinuation.,Dose adjustment required in hepatic impairment.
QT interval prolongation: caution in patients with risk factors for QT prolongation, electrolyte abnormalities, or concomitant use of drugs that prolong QT interval.,Parasite resistance: monitor for clinical failure.,Re-evaluate if severe malaria develops.,Use with caution in patients with hepatic or renal impairment.,Potential for drug interactions with CYP3A4 inducers/inhibitors.
Concomitant use with MAOIs.,History of QT prolongation or congenital long QT syndrome.,Severe hepatic impairment (Child-Pugh Class C).
Hypersensitivity to artemether, lumefantrine, or any component of the formulation.,Concomitant therapy with drugs that are metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, metoprolol, imipramine, amitriptyline, clomipramine) due to potential QT prolongation.,Severe malaria (parenteral therapy recommended).
Avoid grapefruit and grapefruit juice; may increase drug levels. Take with or without food as directed; if GI upset occurs, take with food.
Take with fatty food (e.g., whole milk, cheese, or a meal containing fat) to increase absorption, especially of lumefantrine. Avoid grapefruit juice. Alcohol may increase risk of hepatotoxicity and should be avoided.
First trimester: Known human teratogen; high risk of major congenital malformations (neural tube defects, cardiovascular anomalies, cleft palate). Second and third trimesters: Increased risk of fetal growth restriction, premature birth, and neurodevelopmental impairment. Avoid use in pregnancy unless no safer alternative.
Pregnancy Category C. First trimester: Avoid; teratogenic effects observed in animal studies (skeletal malformations) at clinically relevant doses. Second and third trimesters: Data limited; use only if benefit outweighs risk. Malaria infection poses higher fetal risk than treatment.
Excreted into human breast milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants (e.g., immunosuppression, growth suppression). Contraindicated during breastfeeding; if unavoidable, pump and discard milk for 5 elimination half-lives after last dose.
Artemether and lumefantrine are excreted into breast milk in low amounts. M/P ratio not determined. Based on limited data, the American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for potential adverse effects (diarrhea, vomiting).
No standard dose adjustment; contraindicated in pregnancy. Due to increased plasma volume and hepatic metabolism, if unavoidable, consider therapeutic drug monitoring to maintain trough levels within therapeutic range.
No routine dose adjustment required in pregnancy. Pharmacokinetic studies show no clinically significant changes in artemether or lumefantrine exposure during pregnancy compared to non-pregnant adults. Administer standard weight-based dosing.
GENAPAX is a fictional drug with no established clinical data. Use only in approved clinical trials with appropriate monitoring.
Coartem (artemether/lumefantrine) is a first-line treatment for uncomplicated Plasmodium falciparum malaria. Administer with fatty food to enhance absorption (especially lumefantrine). Monitor for QT prolongation, especially in patients with electrolyte abnormalities, bradycardia, or concurrent use of QT-prolonging drugs. Do not use for severe malaria or as prophylaxis. Not recommended in children <5 kg. Repeat dose if vomiting occurs within 1 hour of administration.
Take exactly as prescribed; do not adjust dose without consulting your healthcare provider.,Report any unusual symptoms or side effects immediately.,Avoid alcohol and grapefruit juice unless cleared by your doctor.,Do not stop taking this drug abruptly; taper as directed.
Take Coartem with a full meal or fatty food (e.g., milk, cheese) to help the medicine work better.,Complete the full course of 6 doses over 3 days even if you feel better.,If you vomit within 1 hour after taking a dose, take another dose with food.,Avoid grapefruit juice during treatment as it may affect the medication.,Report any signs of irregular heartbeat, dizziness, or fainting immediately.,Use effective birth control during treatment and for 1 month after the last dose, as Coartem may reduce hormonal contraceptive effectiveness.,Not to be used for prevention of malaria.,Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENAPAX vs COARTEM, answered by our medical review team.
GENAPAX is a Antimalarial Agent that works by Gepirone is a 5-HT1A receptor partial agonist, enhancing serotonergic neurotransmission in brain regions implicated in mood regulation.. COARTEM is a Antimalarial Agent that works by Artemether and lumefantrine are antimalarial agents that act as blood schizonticides. Artemether is rapidly metabolized to dihydroartemisinin, which generates free radicals that damage parasite proteins and membranes. Lumefantrine inhibits the formation of beta-hematin (hemozoin) by forming a complex with hemin, thereby preventing parasite detoxification of heme.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENAPAX and COARTEM depend on the specific clinical indication. These are both Antimalarial Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENAPAX is: Oral: 500 mg twice daily. Intravenous: 500 mg over 1 hour every 6 hours.. The standard adult dose of COARTEM is: 4 tablets (each containing artemether 20 mg and lumefantrine 120 mg) orally twice daily for 3 days (total of 6 doses). Doses should be taken with fatty food to enhance absorption. Repeat dosing if vomiting occurs within 1 hour after administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENAPAX and COARTEM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENAPAX is classified as Category C. First trimester: Known human teratogen; high risk of major congenital malformations (neural tube defects, cardiovascular anomalies, cleft palate). Second and third trimesters: Incr. COARTEM is classified as Category C. Pregnancy Category C. First trimester: Avoid; teratogenic effects observed in animal studies (skeletal malformations) at clinically relevant doses. Second and third trimesters: Dat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.